Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial

详细信息    查看全文

• 作者：Stephen E. Kimmel ; Benjamin French ; Jeffrey L. Anderson ; Brian F. Gage ; Julie A. Johnson ; Yves D. Rosenberg ; Nancy L. Geller ; Scott E. Kasner ; Charles S. Eby ; Jungnam Joo ; Michael D. Caldwell ; Samuel Z. Goldhaber ; Robert G. Hart ; Denise Cifelli ; Rosemary Madigan ; Colleen M. Brensinger ; Suzanne Goldberg ; Robert M. Califf ; Jonas H. Ellenberg
• 刊名：American Heart Journal
• 出版年：2013
• 出版时间：September, 2013
• 年：2013
• 卷：166
• 期：3
• 页码：435-441.e2
• 全文大小：295 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background

Current dosing practices for warfarin are empiric and result in the need for frequent dose changes as the international normalized ratio gets too high or too low. As a result, patients are put at increased risk for thromboembolism, bleeding, and premature discontinuation of anticoagulation therapy. Prior research has identified clinical and genetic factors that can alter warfarin dose requirements, but few randomized clinical trials have examined the utility of using clinical and genetic information to improve anticoagulation control or clinical outcomes among a large, diverse group of patients initiating warfarin.

Methods

The COAG trial is a multicenter, double-blind, randomized trial comparing 2 approaches to guiding warfarin therapy initiation: initiation of warfarin therapy based on algorithms using clinical information plus an individual's genotype using genes known to influence warfarin response (¡°genotype-guided dosing¡±) versus only clinical information (¡°clinical-guided dosing¡±) ( Identifier: ).

Results

The COAG trial design is described. The study hypothesis is that, among 1,022 enrolled patients, genotype-guided dosing relative to clinical-guided dosing during the initial dosing period will increase the percentage of time that patients spend in the therapeutic international normalized ratio range in the first 4 weeks of therapy.

Conclusion

The COAG will determine if genetic information provides added benefit above and beyond clinical information alone.